Moclobemide and placebo in mild major depression:
a double-blind randomized trial.

Ose E, Holm P
Sandviken Sykehus, 
Sandviken-Bergen, Norway. 
Psychopharmacology (Berl) 1992;106 Suppl:S114-5

ABSTRACT

Sixty-eight patients participated in this double-blind randomized study with moclobemide versus placebo (35 allocated to moclobemide; 33 to placebo). In terms of mean HAMD total scores, improvement tended to be more pronounced in the moclobemide group at treatment end-point. Efficacy was judged to be 'very good' or 'good' in 50% of moclobemide-treated patients and in 27% of placebo-treated patients: in completers only, the difference was more marked (69% versus 33%; P less than 0.05 Mann-Whitney test). Tolerability was judged to be 'very good' or 'good' in 77% of moclobemide-treated patients and in 94% of placebo-treated patients. Adverse events were observed in 31% of patients in the moclobemide group and in 18% of patients in the placebo group.

Moclobemide research
                                                         
 1.    Moclobemide  for the treatment of depression
 2.    Moclobemide  in clinical psychopharmacology
 3.    Moclobemide  therapy for chronic depressive disorders 
 4.    Moclobemide  and tranylcypromine in depression
 5.    Moclobemide  and fluoxetine for panic disorder
 6.    Moclobemide  in patients with dementia and depression
 7.    Moclobemide  in mild major depression
 8.    Moclobemide  for depression
 9.    Moclobemide  in treatment of major depressive episodes
10.   Moclobemide  vs. placebo in the treatment of depression
11.   Moclobemide  long-term treatment in major depression
12.   Moclobemide  and sertraline in the treatment of depression
13.   Moclobemide  in long-term treatment
14.   Moclobemide  vs fluoxetine for double depression
15.   Moclobemide  vs fluoxetine in major depressive disorders
16.   Moclobemide  vs fluoxetine in major depression
         Moclobemide  manufacturer's product insert

 

 

 

Hit Counter